Lotus Bio-Technology Development Corp.
LBTD · OTC
12/31/2017 | 9/30/2017 | 6/30/2017 | 3/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 27.39 | -0.00 | 275.95 | -0.00 |
| FCF Yield | -0.02% | -0.06% | 0.00% | 0.17% |
| EV / EBITDA | -10,699.02 | -107.59 | -111,135.66 | -15.47 |
| Quality | ||||
| ROIC | 5.50% | 138.69% | 0.77% | 1,100.89% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 2.37 | 0.07 | – | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -47.60% | 0.00% | -100.00% | 286.31% |
| Safety | ||||
| Net Debt / EBITDA | 53.57 | -4.60 | -768.99 | -0.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |